Precision Health Clinical Trials

Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma (PRE-MERIDIAN)

Conditions:   Cancer;   Head and Neck Squamous Cell Carcinoma;   Head and Neck Cancer
Sponsors:   University Health Network, Toronto;   Princess Margaret Hospital, Canada

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Condition:   Metastatic Castration-sensitive Prostate Cancer
Intervention:   Drug: Apalutamide
Sponsors:   Kindai University;   Janssen Pharmaceutical K.K.

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

Conditions:   Biliary Tract Neoplasms;   Gastric Cancer;   Esophageal Squamous Cell Carcinoma;   Colorectal Cancer;   Gastrointestinal Stromal Tumors;   Pancreatic Cancer;   Neuroendocrine Tumors;   Unknown Primary Cancer;   Digestive Cancer
Interventions:   Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.;   Drug: Other Therapy
Sponsors:   Peking University;   Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

UW Undiagnosed Genetic Diseases Program

Conditions:   Rare Diseases;   Genetic Disease;   Undiagnosed Disease
Intervention:   Diagnostic Test: Trio Whole Genome Sequencing and Participant-Specific Research
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin Center for Human Genomics and Precision Medicine

Transcriptional and Immine Parameters of Response to Belinumab

Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Belimumab
Sponsor:   Biomedical Research Foundation, Academy of Athens
Not yet recruiting

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Gallbladder Cancer;   Intrahepatic Cholangiocarcinoma;   Perihilar Cholangiocarcinoma;   Extrahepatic Cholangiocarcinoma;   Hilar Cholangiocarcinoma;   Distal Bile Duct Cancer
Intervention:   Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors:   University of Washington;   Natera, Inc.;   SEngine Precision Medicine, Inc.

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

Conditions:   Oropharyngeal Squamous Cell Carcinoma;   Carcinoma, Squamous Cell;   Head and Neck Squamous Cell Carcinoma;   Oropharynx Squamous Cell Carcinoma
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Mayo Clinic

Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools

Condition:   Developmental Disorders
Interventions:   Genetic: genome-wide analyses;   Genetic: Search for de novo mutations in paternal sperm samples
Sponsor:   University Hospital, Rouen
Not yet recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Conditions:   Advanced Breast Carcinoma;   Advanced Gastric Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Ovarian Carcinoma;   Advanced Pancreatic Carcinoma;   Advanced Prostate Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Castration-Resistant Prostate Carcinoma;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   HER2-Positive Breast Carcinoma;   Metastatic Breast Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Ovarian Carcinoma;   Metastatic Pancreatic Carcinoma;   Metastatic Prostate Carcinoma;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Platinum-Sensitive Ovarian Carcinoma;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
Interventions:   Procedure: Biopsy;   Drug: Talazoparib
Sponsor:   National Cancer Institute (NCI)

ANXA5 M2 Haplotyping in IVF Patients and Embryos

Conditions:   Infertility;   Miscarriage, Recurrent;   Pregnancy Complications
Intervention:   Other: M2 Test
Sponsor:   Genomic Prediction Inc.